NCT05559502

Brief Summary

Transnasal humidified rapid-insufflation ventilatory exchange(THRIVE), or also termed high flow nasal oxygenation (HFNO) is a method of supplying heated, humidified high concentrations of oxygen via nasal cavity. This study hypothesizes that in general anesthesia for laryngeal microsurgery, high-flow nasal oxygen without endotracheal intubation reduces cough during the emergence period compared to endotracheal intubation.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
52

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Nov 2022

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 26, 2022

Completed
3 days until next milestone

First Posted

Study publicly available on registry

September 29, 2022

Completed
2 months until next milestone

Study Start

First participant enrolled

November 15, 2022

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2024

Completed
Last Updated

December 27, 2023

Status Verified

December 1, 2023

Enrollment Period

1.6 years

First QC Date

September 26, 2022

Last Update Submit

December 26, 2023

Conditions

Keywords

High flow nasal oxygenationLaryngeal microsurgeryemergence cough

Outcome Measures

Primary Outcomes (1)

  • Grade of Emergence cough during periextubation period

    Grade Score (grade 0=no cough, grade 1=light or single cough, grade 2=moderate cough or more than one episode of nonsustained coughing, grade 3=sustained and repetitive cough movements with head lift, 0 is the minimum value which is a better outcome and 3 is the maximum value which is a worse outcome.)

    From end of surgery to extubation

Secondary Outcomes (1)

  • Number of Participants with postoperative airway complications

    from 1 hour after surgery to 24 hours after surgery

Study Arms (2)

HFNO group

EXPERIMENTAL

Patients will receive HFNO therapy during laryngomicrosurgery.

Device: HFNO group

ET group

ACTIVE COMPARATOR

Endotracheal intubation was performed for general anesthesia

Device: ET group

Interventions

HFNO therapy make possible to perform tubeless anesthesia, providing perfect exposure of structure of the vocal cords.

Also known as: Optiflow
HFNO group
ET groupDEVICE

Endotracheal tube is a plain tube, which is most commonly used in general anesthesia.

Also known as: Portex, Smiths Medical International Ltd., South East England, United Kingdom
ET group

Eligibility Criteria

Age19 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with American Society of Anesthesiologists classification 1 or 2 who receive general anesthesia for laryngeal microsurgery

You may not qualify if:

  • Patients with major cardiovascular, pulmonary, and cerebrovascular disease
  • Laser laryngeal surgery
  • Morbid obesity (BMI\>35 kg/m2)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ajou University Hospital

Suwon, Gyeongki-do, 443-721, South Korea

RECRUITING

MeSH Terms

Conditions

Cough

Condition Hierarchy (Ancestors)

Respiration DisordersRespiratory Tract DiseasesSigns and Symptoms, RespiratorySigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • JongYeop Kim, M.D.,Ph.D.

    Ajou University School of Medicine

    PRINCIPAL INVESTIGATOR

Central Study Contacts

TaeKwang Kim, M.D.

CONTACT

JongYeop Kim, M.D.,Ph.D.

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

September 26, 2022

First Posted

September 29, 2022

Study Start

November 15, 2022

Primary Completion

June 30, 2024

Study Completion

June 30, 2024

Last Updated

December 27, 2023

Record last verified: 2023-12

Locations